A tur­bu­lent 2024 for Neu­ro­crine is end­ing on a high note, af­ter the biotech won FDA ap­proval to treat con­gen­i­tal adren­al hy­per­pla­sia, a con­di­tion marked … ...

After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), Neurocrine Biosciences has scored FDA approval for its first-in-class ...